Kindeva Drug Delivery and Orbia Advance Corporation, S.A.B. de C.V. announced co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura?s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a. This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura?s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice. This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.

The converted pMDI products will be available for licensing with anticipated launches occurring in-line with the expected commencement of a phase-down of existing pMDI systems containing HFC-134a and HFC-227ea within the European Union.